Serum thioredoxin-1 as a diagnostic marker for malignant peritoneal mesothelioma

Journal of Clinical Gastroenterology

Volumn 47, Issue 1, 2013, Pages e7-e11

  Tabata, Chiharu ^a   Terada, Takayuki ^a   Tabata, Rie ^a   Yamada, Shusai ^a   Eguchi, Ryoji ^a   Fujimori, Yoshihiro ^a   Nakano, Takashi ^a  

^a HYOGO COLLEGE OF MEDICINE   (Japan)

Author keywords

Mesothelioma; Thioredoxin; Tumor marker

Indexed keywords

ASBESTOS; THIOREDOXIN 1;

AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; COMPARATIVE STUDY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DIFFUSE MALIGNANT PERITONEAL MESOTHELIOMA; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; PERITONEUM MESOTHELIOMA; PREDICTIVE VALUE; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY;

ADULT; AGED; AGED, 80 AND OVER; EARLY DETECTION OF CANCER; FEMALE; HUMANS; MALE; MESOTHELIOMA; MIDDLE AGED; PERITONEAL NEOPLASMS; PREDICTIVE VALUE OF TESTS; ROC CURVE; SAMPLING STUDIES; SENSITIVITY AND SPECIFICITY; THIOREDOXINS; TUMOR MARKERS, BIOLOGICAL;

EID: 84871619237     PISSN: 01920790     EISSN: 15392031     Source Type: Journal    
DOI: 10.1097/MCG.0b013e31824e901b     Document Type: Article

References (29)

1. Robinson BW, Musk AW, Lake RA. Malignant mesothelioma. Lancet. 2005;366:397-408
2. Robinson BW, Lake RA. Advances in malignant mesothelioma. N Engl J Med. 2005;353:1591-1603
3. Wagner JC, Sleggs CA, Marchand P. Diffuse pleural mesothelioma and asbestos exposure in the North Western Cape Province. Br J Ind Med. 1960;17:260-271
4. Boffetta P. Epidemiology of peritoneal mesothelioma: a review. Ann Oncol. 2007;18:985-990
5. Deraco M, Bartlett D, Kusamura S, et al. Consensus statement on peritoneal mesothelioma. J Surg Oncol. 2008;98:268-272
6. Manzini Vde P, Recchia L, Cafferata M, et al. Malignant peritoneal mesothelioma: a multicenter study on 81 cases. Ann Oncol. 2010;21:348-353
7. Baratti D, Kusamura S, Deraco M. Diffuse malignant peritoneal mesothelioma: systematic review of clinical management and biological research. J Surg Oncol. 2011;103:822-831
8. Yan TD, Deraco M, Baratti D, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience. J Clin Oncol. 2009;27:6237-6242
9. Robinson BW, Creaney J, Lake R, et al. Mesothelin-family proteins and diagnosis of mesothelioma. Lancet. 2003;362:1612-1616
10. Pass HI, Lott D, Lonardo F, et al. Asbestos exposure, pleural mesothelioma, and serum osteopontin levels. N Engl J Med. 2005;353:1564-1573
11. Rake C, Gilham C, Hatch J, et al. Occupational, domestic and environmental mesothelioma risks in the British population: a case-control study. Br J Cancer. 2009;100:1175-1183
12. Selikoff IJ, Hammond EC, Seidman H. Latency of asbestos disease among insulation workers in the United States and Canada. Cancer. 1980;15:2736-2740
13. Kamp DW, Weitzman SA. The molecular basis of asbestos induced lung injury. Thorax. 1999;54:638-652
14. Holmgren A. Thioredoxin. Annu Rev Biochem. 1985;54:237-271
15. Tagaya Y, Maeda Y, Mitsui A, et al. ATL-derived factor (ADF), an IL-2 receptor/Tac inducer homologous to thioredoxin; possible involvement of dithiol-reduction in the IL-2 receptor induction. EMBO J. 1989;8:757-764
16. Bertoglio J, Wollman E, Shaw A, et al. Identification of interleukin 1 alpha produced by the 3B6 human EBV-B cell line. Lymphokine Res. 1989;8:19-24
17. Nakamura H, Nakamura K, Yodoi J. Redox regulation of cellular activation. Annu Rev Immunol. 1997;15:351-369
18. Nakamura H, Masutani H, Yodoi J. Redox imbalance and its control in HIV infection. Antioxid Redox Signal. 2002;4:455-464
19. Sumida Y, Nakashima T, Yoh T, et al. Serum thioredoxin levels as an indicator of oxidative stress in patients with hepatitis C virus infection. J Hepatol. 2000;33:616-622
20. Takagi Y, Mitsui A, Nishiyama A, et al. Overexpression of thioredoxin in transgenic mice attenuates focal ischemic brain damage. Proc Natl Acad Sci USA. 1999;96:4131-4136
21. Hoshino T, Nakamura H, Okamoto M, et al. Redox-active protein thioredoxin prevents proinflammatory cytokine- or bleomycin-induced lung injury. Am J Respir Crit Care Med. 2003;168:1075-1083
22. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med. 1971;285:1182-1186
23. Kim HJ, Chae HZ, Kim YJ, et al. Preferential elevation of Prx I and Trx expression in lung cancer cells following hypoxia and in human lung cancer tissues. Cell Biol Toxicol. 2003;19:285-298
24. Soini Y, Kahlos K, Näpänkangas U, et al. Widespread expression of thioredoxin and thioredoxin reductase in non-small cell lung carcinoma. Clin Cancer Res. 2001;7:1750-1757
25. Park JH, Kim YS, Lee HL, et al. Expression of peroxiredoxin and thioredoxin in human lung cancer and paired normal lung. Respirology. 2006;11:269-275
26. Arnér ES, Holmgren A. The thioredoxin system in cancer. Semin Cancer Biol. 2006;16:420-426
27. Rihn BH, Mohr S, McDowell SA, et al. Differential gene expression in mesothelioma. FEBS Lett. 2000;480:95-100
28. Kahlos K, Soini Y, Säily M, et al. Up-regulation of thioredoxin and thioredoxin reductase in human malignant pleural mesothelioma. Int J Cancer. 2001;95:198-204
29. Maeda R, Tabata C, Tabata R, et al. Is serum thioredoxin-1 a useful clinical marker for malignant pleural mesothelioma? Antioxid Redox Signal. 2011;15:685-689